A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML. - Brunner AM; Liu Y; Garcia JS; Mendez LM; Gutierrez C; Nonavinkere Srivatsan S; Shao J; Aubrey BJ; Amrein PC; Narayan R; Vedula RS; Friedman E; et al. (Blood advances, 2026)